CDK4 and psoriasis: Repurposing of CDK4/6 or methyltransferase EZH2 inhibitors may thus serve as therapeutic target for patients with psoriasis.548 Accordingly, topical administration of palbociclib resulted in reduced erythema, inflammation, desquamation and scaling in a mouse model of psoriasiform dermatitis.546,548,549